Full text is available at the source.
Abstract
Assessing capping efficiency in mRNA therapeutics remains challenging due to its minimal contribution to overall molecular mass.
- Capping efficiency is a crucial quality attribute for mRNA therapeutics.
- Distinguishing capped from uncapped mRNA requires sensitive analytical instrumentation and multistep sample preparation.
- 5'-end heterogeneity can arise from transcription, capping, and analysis, complicating efficiency assessments.
- Current strategies for evaluating mRNA capping efficiency and cap composition are reviewed.
- Identified sources of 5'-end heterogeneity are characterized in methodological studies.
Simplified